Merck KGaA, Darmstadt, Germany, and Pfizer Announce First Patient Treated in Phase III Combination Study with Avelumab and INLYTA® in Renal Cell Carcinoma

Go back to Merck KGaA, Darmstadt, Germany, and Pfizer Announce First Patient Treated in Phase III Combination Study with Avelumab and INLYTA® in Renal Cell Carcinoma
Pfizer Inc. (NYSE: PFE) Delayed: 30.42 +0.47 (1.57%)
Previous Close $29.95    52 Week High $37.39 
Open $30.51    52 Week Low $28.25 
Day High $30.65    P/E 18.44 
Day Low $30.14    EPS $1.65 
Volume 9,915,350